Free Trial

Oxford BioDynamics (OBD) Competitors

Oxford BioDynamics logo
GBX 0.48 +0.03 (+7.71%)
As of 12:23 PM Eastern

OBD vs. SAR, POLB, COS, C4XD, DDDD, APTA, FUM, AREC, OKYO, and AOR

Should you be buying Oxford BioDynamics stock or one of its competitors? The main competitors of Oxford BioDynamics include Sareum (SAR), Poolbeg Pharma (POLB), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Aptamer Group (APTA), Futura Medical (FUM), Arecor Therapeutics (AREC), OKYO Pharma (OKYO), and AorTech International (AOR). These companies are all part of the "biotechnology" industry.

Oxford BioDynamics vs. Its Competitors

Oxford BioDynamics (LON:OBD) and Sareum (LON:SAR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

In the previous week, Sareum had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for Sareum and 0 mentions for Oxford BioDynamics. Sareum's average media sentiment score of 0.67 beat Oxford BioDynamics' score of 0.00 indicating that Sareum is being referred to more favorably in the news media.

Company Overall Sentiment
Oxford BioDynamics Neutral
Sareum Positive

11.4% of Oxford BioDynamics shares are held by institutional investors. 15.5% of Oxford BioDynamics shares are held by insiders. Comparatively, 36.6% of Sareum shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oxford BioDynamics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Sareum has a beta of -1.08, indicating that its share price is 208% less volatile than the S&P 500.

Sareum has lower revenue, but higher earnings than Oxford BioDynamics. Sareum is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£896K10.38-£103.52M-£0.03-16.38
SareumN/AN/A-£5.28M-£0.03-1,036.54

Sareum has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,800.32%. Sareum's return on equity of -270.25% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-1,800.32% -289.38% -56.23%
Sareum N/A -270.25%-113.80%

Summary

Sareum beats Oxford BioDynamics on 7 of the 12 factors compared between the two stocks.

Get Oxford BioDynamics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBD vs. The Competition

MetricOxford BioDynamicsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£9.30M£228.13M£5.74B£2.58B
Dividend YieldN/A3.78%5.53%5.33%
P/E Ratio-16.3831.8376.355,412.34
Price / Sales10.384,691.56466.9197,600.50
Price / Cash3.9813.1937.4627.93
Price / Book0.59123.6213.188.71
Net Income-£103.52M-£90.99M£3.29B£5.89B
7 Day Performance1.06%0.57%2.50%1.14%
1 Month PerformanceN/A18.59%4.60%3.07%
1 Year Performance-86.88%664.38%73.81%175.61%

Oxford BioDynamics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBD
Oxford BioDynamics
N/AGBX 0.48
+7.7%
N/A-88.1%£9.30M£896K-16.3845Gap Up
SAR
Sareum
N/AGBX 23.25
-6.1%
N/A+3.8%£31.90MN/A-894.233,211
POLB
Poolbeg Pharma
N/AGBX 4.45
-3.3%
N/A-59.6%£31.03MN/A-383.6212News Coverage
COS
Collagen Solutions plc (COS.L)
N/AN/AN/AN/A£30.99M£4.01M-8.283,350
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049High Trading Volume
DDDD
4D pharma
N/AN/AN/AN/A£30.05M£718K-1.08106
APTA
Aptamer Group
N/AGBX 1.07
-2.8%
N/A+284.6%£28.83M£1.22M-381.7937Positive News
Gap Up
FUM
Futura Medical
N/AGBX 9.34
-6.4%
N/A-85.9%£28.37M£13.93M2,277.3212Gap Up
AREC
Arecor Therapeutics
N/AGBX 74.57
+2.9%
N/A+8.9%£28.16M£5.05M-240.5510
OKYO
OKYO Pharma
N/AN/AN/AN/A£23.24MN/A-140.007Gap Down
AOR
AorTech International
N/AN/AN/AN/A£19.99M£539K-33.383

Related Companies and Tools


This page (LON:OBD) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners